drugset / Trial / NCT01329250
Pharmacokinetics and Safety of Moxifloxacin
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main objective of this prospective clinical trial is to compare pharmacokinetics and safety and tolerability of a standard dose (400 mg) with an escalated dose (600 mg; 800 mg) of moxifloxacin (MFX). This clinical trial will provide important safety information on MFX in a higher dosage in TB patients.
Timeline
- Start
- 2011-05
- Primary completion
- 2015-06
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 800 mg | — |